Angeles Secord
MD, MHSc
Professor
Duke

Dr. Angeles Alvarez Secord, M.D., M.H.Sc., is a Professor in the Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Duke University Heath System. She graduated AOA with Honors from the University of Washington School of Medicine in Seattle, Washington. Dr. Secord completed her residency in Obstetrics and Gynecology and her fellowship in Gynecologic Oncology at the Duke University Medical Center in Durham, North Carolina. Upon completing her fellowship in 2001, she joined the Division of Gynecologic Oncology at Duke. She is currently the Director of Gynecologic Oncology Clinical Trials, the Associate Director of Clinical Research, Gynecology Oncology, and one of the Principal Investigators for NRG Oncology at the Duke Cancer Institute. Dr. Secord has served as a board member for several professional organizations including Society of Gynecologic Oncology (SGO), GOG Foundation, and American Association of Gynecology and Obstetrics Foundation (AAOGF). She is passionate about mentoring the next generation of investigators and previously served as the AAOGF Scholar Committee Chair, and currently serves as the NRG Oncology New Investigator Committee Vice-Chair and the GOG Foundation Education and Mentoring Co-Chair. Her experience with these associations inspired the SGO theme for the year, “The Power of Shared Purpose: Transforming Gynecologic Cancer Care” and represents the goal to maximally leverage opportunities for synergistic collaboration to further our collective missions and vision where everyone has the power to impact, prevent; overcome, and eradicate gynecologic cancer.

Sessions

Register
General Session

Session 11: Debate: How Should Novel Agents Be Sequenced in the Platinum Resistant Tumor? - Novel Agents and Combinations May Outperform Aurelia and We Can Do Better

Saturday, May 04, 2024
11:10 AM - 11:25 AM
General Session

Session 11: Debate: How Should Novel Agents Be Sequenced in the Platinum Resistant Tumor? - DISCUSSION

Saturday, May 04, 2024
11:25 AM - 11:35 AM
General Session

Session 16: Debate: In What Setting Should Immune Checkpoint Inhibitors (ICIs) Be Incorporated into the Treatment of Endometrial Cancer? - Only in the Front Line Metastatic Setting

Saturday, May 04, 2024
4:10 PM - 4:25 PM
General Session

Session 16: Debate: In What Setting Should Immune Checkpoint Inhibitors (ICIs) Be Incorporated into the Treatment of Endometrial Cancer? - DISCUSSION

Saturday, May 04, 2024
4:25 PM - 4:35 PM
General Session

Case Discussions

Friday, November 01, 2024
2:15 PM - 2:55 PM
General Session

Debate: For Patients Who Have Progressed on (Or Following) PARPI Maintenance, What Is the Best Strategy for Treating Platinum-Sensitive Recurrent Disease? – It's Time to Move on From Platinum

Friday, November 01, 2024
4:20 PM - 4:35 PM
General Session

Debate: For Patients Who Have Progressed on (Or Following) PARPI Maintenance, What Is the Best Strategy for Treating Platinum-Sensitive Recurrent Disease? Platinum is the SOC vs It's Time to Move on From Platinum - DISCUSSION

Friday, November 01, 2024
4:35 PM - 4:45 PM